Abstract
Pheochromocytoma is a rare cause of cardiogenic shock. Clinical management is directed at reducing the heart rate while maintaining blood pressure. However, medical treatment is often unsuccessful because of the high endogenous catecholamine level and low cardiac output. Percutaneous cardiopulmonary bypass system is a circulatory device that allows for safer use of heart-rate-reducing agents, which is advantageous when used early in the course of the cardiogenic shock induced by pheochromocytoma.
MeSH terms
-
Adrenal Gland Neoplasms / complications*
-
Adrenal Gland Neoplasms / diagnosis
-
Adrenal Gland Neoplasms / physiopathology
-
Adrenal Gland Neoplasms / surgery
-
Adrenalectomy
-
Adult
-
Anti-Arrhythmia Agents / therapeutic use
-
Blood Pressure
-
Cardiopulmonary Bypass*
-
Cardiotonic Agents / therapeutic use
-
Diuretics / therapeutic use
-
Electrocardiography
-
Femoral Artery
-
Femoral Vein
-
Heart Rate
-
Humans
-
Intra-Aortic Balloon Pumping
-
Male
-
Pheochromocytoma / complications*
-
Pheochromocytoma / diagnosis
-
Pheochromocytoma / physiopathology
-
Pheochromocytoma / surgery
-
Pulmonary Edema / etiology
-
Pulmonary Edema / therapy
-
Shock, Cardiogenic / etiology
-
Shock, Cardiogenic / physiopathology
-
Shock, Cardiogenic / therapy*
-
Tomography, X-Ray Computed
-
Treatment Outcome
Substances
-
Anti-Arrhythmia Agents
-
Cardiotonic Agents
-
Diuretics